Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases. The company is developing its lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical need. The company's mission is to use optogenetics to restore vision, independent of genetic mutation for patients with inherited retinal diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/04/22 | $6,000,000 | Seed |
4BIO Capital | undisclosed |
| 05/16/23 | $100,000,000 | Series A |
4BIO Capital Deerfield Management Company, L.P. MRL Ventures Fund Norwest Venture Partners Novo Holdings  Platanus | undisclosed |
